Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Shionogi Reports Positive Results from Cefiderocol Phase III Study in Adults with Pneumonia Caused by Gram-negative Pathogens

Shionogi & Co. Ltd. announced results from APEKS-NP, an international, double-blind, randomized Phase III clinical trial evaluating the efficacy and safety of the investigational antibiotic cefiderocol in patients with nosocomial pneumonia (NP).

Read More »

Dana-Farber Confirms Accuracy of Cancer Blood Test

A new blood test in development from GRAIL Inc. and studied by investigators at the Dana-Farber Cancer Institute has the ability to accurately screen for numerous types of cancer.

Read More »

AstraZeneca strengthens Lynparza push with prostate cancer data

AstraZeneca presented results for a late-stage clinical trial of Lynparza against prostate cancer, which the company hopes could lead to wider regulatory approval for more forms of the disease.

Read More »

Positive Data Reported for Merck’s Keytruda Plus Chemo Combo as Neoadjuvant Therapy in Early-Stage TNBC

Merck announced results from the pivotal neoadjuvant/adjuvant Phase 3 KEYNOTE-522 trial in patients with early-stage triple-negative breast cancer (TNBC).

Read More »

Bristol-Myers immunotherapy combo outperforms chemo in lung cancer survival: study

About 40 percent of patients who received a combination of Bristol-Myers Squibb Co.’s immuno-oncology drugs Opdivo and Yervoy as an initial treatment for advanced non-small cell lung cancer were alive after two years, according to data presented at the European Society for Medical Oncology 2019 meeting.

Read More »

Results of GSK and AstraZeneca trials may widen ovarian cancer drug use

GlaxoSmithKline and AstraZeneca both reported late-stage clinical trial results that will likely make their competing medicines available to a wider group of ovarian cancer patients, possibly helping GSK catch the company’s rival in a highly contested drug class.

Read More »

Genentech’s Tecentriq Improves OS as First-line Monotherapy in Certain People With Advanced NSCLC

Genentech announced positive data from the Phase III IMpower110 study evaluating Tecentriq as a first-line monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine (chemotherapy) in advanced non-squamous and squamous non-small cell lung cancer (NSCLC) without ALK or EGFR mutations (wild-type; WT).

Read More »

SPARTAN Study Shows 25 Percent Reduction in the Risk of Death in Patients with nmCRPC Treated with Erleada

Treatment with Janssen’s Erleada plus androgen deprivation therapy (ADT) resulted in a 25 percent reduction in the risk of death compared with placebo plus ADT in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who were at high risk of developing metastases.

Read More »

Pfizer’s Atopic Dermatitis Drug Hits the Mark in Second Phase III Trial

Pfizer’s oral Janus kinase 1 (JAK1) inhibitor abrocitinib hit the primary endpoint in a second Phase III study in patients 12 and older with moderate to severe atopic dermatitis.

Read More »

Brilinta demonstrates benefit in Patients with High-Bleeding Risk PCI

New data from TWILIGHT – a Phase IV independent trial funded by AstraZeneca – showed that in patients at high-bleeding risk who underwent PCI and completed three months of dual antiplatelet therapy, Brilinta monotherapy (90 mg twice daily) reduced the risk of BARC (Bleeding Academic Research Consortium) type 2, 3 or 5 bleeding compared to Brilinta plus low-dose aspirin after 12 months.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom